Post-Marketing Safety Studies Could Be Funded By User Fees, Cmte. Suggests
Executive Summary
User fees to fund post-marketing safety assessments should be considered in negotiations for the reauthorization of the Prescription Drug User Fee Act, a former FDA official and member of the Drug Safety & Risk Management Advisory Committee suggested
You may also be interested in...
Drug Safety Bill Authorizes Fines On Industry, But Does Not Include User Fees
The Center for Postmarket Drug Evaluation & Research proposed in legislation from Sens. Grassley and Dodd would be funded by appropriations, not user fees
FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals
Postmarketing safety legislation proposed by Senate Finance Committee Chairman Charles Grassley (R-Iowa) and Sen. Chris Dodd (D-Conn.) calls for FDA to establish "expedited procedures" for drug withdrawals
Phase IV Status Report: Fewer Open Studies, But More Overdue Reports
The pharmaceutical industry had 67% fewer drugs and biologics with open Phase IV commitments in fiscal year 2004 than the previous year, FDA's postmarketing database shows